Investor Relations
Skip to content
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact
ViruCure
  • Home
  • About
    • Our Story
    • Team
  • Products
    • Our Products
    • Product Pipeline
  • NADAV Technology
  • Clinical
    • Phase 1/2
    • Preclinical
    • Publications
  • News
  • Contact

Month: June 2018

Join ViruCure at the Immuno Oncology Summit Europe 2018, 27-31 August, Boston, USA

June 28, 2018August 2, 2018

Powering next generation targeted immunotherapies, come and meet with our CTO, Shay Tayeb, and learn more about NADAV – our novel oncolytic virus platform technology.

Learn More
Categories news

ViruCure to attend the Armed Oncolytic Immunotherapies Summit Europe 2018, 26-28 June, Frankfurt, Germany

June 20, 2018August 2, 2018

Meet with our CTO, Shay Tayeb, at the leading end-to-end meeting focused on the next generation of oncolytic virus therapies and discover more about ViruCure’s oncolytic virus technology, NADAV.

Learn More
Categories news

Recent Posts

  • Join ViruCure at the Immuno Oncology Summit Europe 2018, 27-31 August, Boston, USA
  • ViruCure to attend the Armed Oncolytic Immunotherapies Summit Europe 2018, 26-28 June, Frankfurt, Germany
  • ViruCure to attend the Biotechnology Innovation Organization, 4-7 June, Boston, USA

Recent Comments

    Archives

    • June 2018
    • May 2018

    Categories

    • news

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    info@virucure.com

    Linkedin

    ViruCure Therapeutics

    ViruCure Therapeutics is a biotech company that is developing an oncolytic-virus-based technology platform, NADAV, for the targeted treatment of a wide range of cancers.

    © 2018 • ViruCure